banner USF Home College of Arts & Sciences OASIS myUSF USF A-Z Index

USF Home > College of Arts and Sciences > Cancer Biology Ph.D. Program

Jason  Dubovsky

Jason Dubovsky

Jason Dubovsky

  

Bio

fiogf49gjkf0d

Dr. Jason Dubovksy, pictured above with his committee, successfully defended his dissertation on February 18, 2011. From left to right: Co-Major Professor Eduardo Sotomayor, Committee members Sheng Wei, Lori Hazlehurst and Gary Reuther, Major Professor Javier Pinilla-Ibarz, Jason and his Dissertation Chair Neil E. Kay, Mayo Clinic, Rochester. Dr. Dubovsky initially joined the lab of Dr. John Byrd, Ohio State University Medical Center. He subsequently accepted a position with Pharmacyclics, an AbbVie Company.

Dr. Dubovsky's publication record while in the Program:

Dubovsky JA, Powers JJ, Gao Y, Mariusso LF, Sotomayor EM, Pinilla-Ibarz JA. Epigenetic repolarization of T lymphocytes from chronic lymphocytic leukemia patients using 5-aza-2'-deoxycytidine. Leuk Res. 2011 Sep;35(9):1193-9.

Powers JJ, Dubovsky JA, Epling-Burnette PK, Moscinski L, Zhang L, Mustjoki S, Sotomayor EM, Pinilla-Ibarz JA. A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma. 2011 Apr;52(4):668-79.

Jason A. Dubovsky, Daniel Wang, John J. Powers, Emmanuel Berchmans, Matthew A. Smith, Kenneth L. Wright, Eduardo M. Sotomayor, Javier A. Pinilla-Ibarz. Restoring the Functional Immunogenicity of Chronic Lymphocytic Leukemia Using Epigenetic Modifiers. Leukemia Research. 2011 Mar;35(3):394-404.

Dubovsky JA, Villagra A, Powers JJ, Wang HW, Pinilla-Ibarz J, Sotomayor EM. Circumventing immune tolerance through epigenetic modification. Curr Pharm Des. 2010;16(3):268-76. Review.

Dubovsky JA, McNeel DG, Powers JJ, Sotomayor EM, Pinilla-Ibarz JA. Treatment of Chronic Lymphocytic Leukemia with a Hypomethylating Agent Induces Expression of NXF2, an Immunogenic Cancer Testis Antigen. Clin Cancer Res. 2009 May 15;15(10):3406-15.

Pinilla-Ibarz J, Shah B, Dubovsky JA.The biological basis for immunotherapy in patients with chronic myelogenous leukemia. Cancer Control. 2009 Apr;16(2):141-52.

Dr. Dubovsky's publication record since graduation:

Natarajan G, Terrazas C, Oghumu S, Varikuti S, Dubovsky JA, Byrd JC, Satoskar AR. Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells. Oncoimmunology. 2015 Jun 9;5(1):e1057385. eCollection 2016.PMID: 26942065

Stiff A, Trikha P, Wesolowski R, Kendra K, Hsu V, Uppati S, McMichael EL, Duggan M, Campbell A, Keller K, Landi I, Zhong Y, Dubovsky J, Howard JH, Yu L, Harrington B, Old M, Reiff S, Mace T, Tridandapani S, Muthusamy N, Caligiuri M, Byrd JC, Carson WE 3rd. Myeloid-derived suppressor cells express Bruton's tyrosine kinase and can be depleted in tumor bearing hosts by ibrutinib treatment. Cancer Res. 2016 Feb 15.PMID: 26880800

Harshman SW, Canella A, Ciarlariello PD, Agarwal K, Branson OE, Rocci A, Cordero H, Phelps MA, Hade EM, Dubovsky JA, Palumbo A, Rosko A, Byrd JC, Hofmeister CC, Benson DM Jr, Paulaitis ME, Freitas MA, Pichiorri F. Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers. J Proteomics. 2016 Mar 16;136:89-98. PMID: 26775013

Fabbro SK, Smith SM, Dubovsky JA, Gru AA, Jones JA. Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias. JAMA Oncol. 2015 Aug;1(5):684-6. PMID: 26182170

Liu TM, Woyach JA, Zhong Y, Lozanski A, Lozanski G, Dong S, Strattan E, Lehman A, Zhang X, Jones JA, Flynn J, Andritsos LA, Maddocks K, Jaglowski SM, Blum KA, Byrd JC, Dubovsky JA, Johnson AJ. Hypermorphic mutation of phospholipase C, y2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. Blood. 2015 Jul 2;126(1):61-8. doi: 10.1182/blood-2015-02-626846. Epub 2015 May 13. PMID: 25972157

Dubovsky JA, Flynn R, Du J, Harrington BK, Zhong Y, Kaffenberger B, Yang C, Towns WH, Lehman A, Johnson AJ, Muthusamy N, Devine SM, Jaglowski S, Serody JS, Murphy WJ, Munn DH, Luznik L, Hill GR, Wong HK, MacDonald KK, Maillard I, Koreth J, Elias L, Cutler C, Soiffer RJ, Antin JH, Ritz J, Panoskaltsis-Mortari A, Byrd JC, Blazar BR. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest. 2014 Nov;124(11):4867-76. doi: 10.1172/JCI75328. Epub 2014 Oct 1. PMID: 25271622

Dong S, Guinn D, Dubovsky JA, Zhong Y, Lehman A, Kutok J, Woyach JA, Byrd JC, Johnson AJ. IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells. Blood. 2014 Dec 4;124(24):3583-6. doi: 10.1182/blood-2014-07-587279. Epub 2014 Sep 25.PMID: 25258342

Zhong Y, Byrd JC, Dubovsky JA. The B-cell receptor pathway: a critical component of healthy and malignant immune biology. Semin Hematol. 2014 Jul;51(3):206-18. doi: 10.1053/j.seminhematol.2014.05.007. Epub 2014 May 15. Review. PMID: 25048784

Flynn R, Du J, Veenstra RG, Reichenbach DK, Panoskaltsis-Mortari A, Taylor PA, Freeman GJ, Serody JS, Murphy WJ, Munn DH, Sarantopoulos S, Luznik L, Maillard I, Koreth J, Cutler C, Soiffer RJ, Antin JH, Ritz J, Dubovsky JA, Byrd JC, MacDonald KP, Hill GR, Blazar BR. Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. Blood. 2014 Jun 19;123(25):3988-98. doi: 10.1182/blood-2014-03-562231. Epub 2014 May 12.PMID: 24820310

Zhong Y, El-Gamal D, Dubovsky JA, Beckwith KA, Harrington BK, Williams KE, Goettl VM, Jha S, Mo X, Jones JA, Flynn JM, Maddocks KJ, Andritsos LA, McCauley D, Shacham S, Kauffman M, Byrd JC, Lapalombella R. Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells. Leukemia. 2014 May;28(5):1158-63. doi: 10.1038/leu.2014.9. Epub 2014 Jan 13. No abstract available. PMID: 24413321

Woyach JA, Bojnik E, Ruppert AS, Stefanovski MR, Goettl VM, Smucker KA, Smith LL, Dubovsky JA, Towns WH, MacMurray J, Harrington BK, Davis ME, Gobessi S, Laurenti L, Chang BY, Buggy JJ, Efremov DG, Byrd JC, Johnson AJ. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood. 2014 Feb 20;123(8):1207-13. doi: 10.1182/blood-2013-07-515361. Epub 2013 Dec 5. PMID: 24311722

Dubovsky JA, Chappell DL, Harrington BK, Agrawal K, Andritsos LA, Flynn JM, Jones JA, Paulaitis ME, Bolon B, Johnson AJ, Byrd JC, Muthusamy N. Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing. Blood. 2013 Nov 7;122(19):3308-16. doi: 10.1182/blood-2013-05-504597. Epub 2013 Sep 5. PMID: 24009233

Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY, Larkin KM, Stefanovski MR, Chappell DL, Frissora FW, Smith LL, Smucker KA, Flynn JM, Jones JA, Andritsos LA, Maddocks K, Lehman AM, Furman R, Sharman J, Mishra A, Caligiuri MA, Satoskar AR, Buggy JJ, Muthusamy N, Johnson AJ, Byrd JC. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013 Oct 10;122(15):2539-49. doi: 10.1182/blood-2013-06-507947. Epub 2013 Jul 25.